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Background 21
Copy number variants (CNVs) are an important class of biological variation. They can cause 22 monogenic disease (1, 2), are associated with polygenic traits (3) and may exert pharmacogenetic 23 effects(4). CNVs are structural rearrangements where bases are gained (duplication) or lost 24 (deletion) from the genome causing an altered copy number compared to the reference. 25
The importance of CNVs is highlighted by the role they play in many diseases, including cancers (5), 26 autism (6), developmental disorders (7), and heart disease (8) . Single or partial gene deletions can 27 cause disease where haploinsufficiency would result in the disease phenotype. For example, both 28 single nucleotide variants and whole gene deletions of PKD1 cause polycystic kidney disease (1). 29
Duplications can also result in disease as a result of gene disruption at the site of insertion or 30 through increased gene expression. For example, paternal duplication of the chromosome 6q24 31 region causes neonatal diabetes by overexpression of the imprinted gene PLAGL1 (2, 9) . Larger CNVs 32 are likely to cause syndromic disease as they affect multiple genes. An extreme case is Down 33 syndrome where duplication of chromosome 21 results in characteristic facial features and 34 intellectual disability (10) . 35 CNVs can be detected by a range of methods. In the clinical setting DNA microarrays are routinely 36 used to detect larger rearrangements whilst multiplex ligation-dependent probe amplification 37 (MLPA) is often used to detect single or partial gene CNVs (11). With next generation sequencing 38 (NGS) increasingly employed to investigate genetic variation, the detection of CNVs from NGS data 39 has become increasingly important. While genome sequencing is the optimal method to capture all 40 sequence variation across the genome, due to speed and cost exome sequencing and targeted NGS 41 panels are the most commonly used testing methods, particularly as a first line test in clinical 42 diagnostic laboratories. 43
Many methods have been published to call CNVs from exome and targeted gene panel data (12) . 44
These are designed to detect CNVs within the genes which are targeted by the assay, however 45 biologically interesting and disease causing CNVs will often fall outside of the targeted regions. 46 Existing methods will typically be able to identify if a particular gene is deleted/duplicated however 47 they will not necessarily be able to map the extent of the CNV as the breakpoints will often be 48 located outside the targeted regions. 49 Current approaches to gene targeting for NGS are imperfect. Samuels et al reported that between 50 40% and 60% of sequence reads generated map outside the target regions (13). This in effect 51 produces ultra-low depth genome sequence data. While there is insufficient information (<1X 52 coverage) to call single nucleotide variants over the untargeted region this 'off target' data can be 53 exploited to call large CNVs by detecting read depth changes over a wide area. The ability to use off-54 target reads to call CNVs across the genome increases the diagnostic utility of targeted next-55 generation sequencing panels and also allows for more accurate mapping of breakpoints of CNVs 56 which reside outside of the targeted regions. Previous tools have been designed to detect CNVs in 57 off-target reads from exome data (14) and large targeted panels (15). 58
We have developed a new tool, SavvyCNV, for calling CNVs from off-target reads. We investigated 59 the utility of SavvyCNV by comparing it to the current state of the art tools for calling CNVs in two 60 different truth sets of CNVs from targeted panels and a truth set from exome data. We then used 61
SavvyCNV in a patient cohort tested with a small targeted gene panel (75 genes) to perform a 62 genome-wide analysis to detect CNVs of clinical relevance. 63
Results

64
How much off-target read data is there? 65
For our small targeted panel (16) of 75 genes, 3.4 (SD 1.6) million reads are sequenced on average 66 per sample. 55% (SD 10%) of these map to off-target regions of the genome. This gives a mean read 67 depth in off-target regions of 0.065 (SD 0.044). In the exome samples that we used as a 68 benchmarking data set there are an average of 76 (SD 20) million reads per sample with 20.3% (SD 69 6.6%) off-target, equating to mean read depth of 0.52 (SD 0.20) in off-target regions. This compares 70 to a typical genome sequencing experiment where sufficient reads are sequenced to give >30X mean 71 coverage across the genome. 72
SavvyCNV can call off-target CNVs from targeted panels 73
To evaluate SavvyCNV's ability to call off-target CNVs accurately from targeted panel data we 74 benchmarked its performance against a truth set (see Methods) and compared it to four other tools 75 for calling CNVs: GATK gCNV(17), DeCON(18), EXCAVATOR2(14) and CNVkit(15). To prevent bias due 76 to software configuration tuning, we ran all five tools with multiple configurations, and plotted the 77 best results for each tool on a precision-recall graph (Figure 1 ). The best recall (sensitivity) where 78 precision is at least 50% is shown in Table 1 . 79
Figure 1. Benchmarking off-target CNV calling from targeted panel data. 81
The data points on the plot are generated by a parameter sweep for each tool and show the 82 precision and recall that can be achieved with each tool. The f statistic is the harmonic mean of 83 precision and recall (see methods for details). All four tools called all of the CNVs larger than 5Mb, however only SavvyCNV did so without any false 95 positive calls. All CNVs larger than 1Mb were called by SavvyCNV, GATK gCNV, and DeCON, although 96
SavvyCNV called the most (97.6%) at a precision of above 50%. For all CNVs, SavvyCNV had the 97 highest recall (25.5%) with precision above 50%. For all three CNV size categories, SavvyCNV had the 98 greatest detection power. It can call CNVs that are larger than 1Mb from off-target reads from a 99 targeted panel with good recall (97.6%) and precision (78.8%). 100
SavvyCNV can call on-target CNVs from targeted panels 101
To evaluate the performance of SavvyCNV at calling CNVs from on-target data we used the ICR96 102 validation series(19). ICR96 is a set of 96 samples sequenced using a small targeted sequencing panel 103
(TruSight Cancer Panel v2, 100 genes), with exon CNVs detected independently using MLPA (25 104 single-exon CNVs, 43 multi-exon CNVs, and 1752 normal copy number genes). SavvyCNV had the 105 highest recall for precision over 50% though GATK gCNV and DeCON also performed well -all 3 tools 106 had a recall >95% (Table 2) . Precision can only be compared between tools if recall is identical. While 107 GATK gCNV achieves 85.7% precision at its highest recall of 97.1%, SavvyCNV has a precision of 108 93.0% at the same recall (this is shown in Figure 2 ). DeCON was the next-best performing tool while 109 CnvKit did not call the majority of CNVs. Excavator2 did not run on this data set. Figure Two of the CNVs within the ICR96 dataset cover less than a complete exon and have one breakpoint 129 within the targeted region. These two CNVs are the hardest to detect by read-depth methods, as the 130 read depth is only altered over a fraction of the exon area. Both CNVs are detected only by 131 SavvyCNV, even when the highest sensitivity settings are used with the other CNV callers. 132
Multi-exon CNVs are easier to detect than single-exon CNVs. SavvyCNV, GATK gCNV, and DeCON can 133 detect all 43 multi-exon CNVs, although only SavvyCNV and GATK gCNV did this with a precision 134 greater than 50%. The data points on the plot are generated by a parameter sweep for each tool and show the 138 precision and recall that can be achieved with each tool. The f statistic is the harmonic mean of 139 precision and recall (see methods for details).
SavvyCNV can call off-target CNVs from exome data 141
To assess SavvyCNV's ability to call CNVs from off-target reads generated by exome sequencing we 142 benchmarked it against a truth set (see Methods) and compared its performance to GATK gCNV, 143 DeCON, EXCAVATOR2, and CNVkit. The best recall where precision is at least 50% is shown in Table 3  144 for two different size categories, and recall/precision is shown in Figure 3 The data points on the plot are generated by a parameter sweep for each tool and show the 154 precision and recall that can be achieved with each tool. The f statistic is the harmonic mean of 155 precision and recall (see methods for details). 156 Having validated the ability of SavvyCNV to call CNVs from off-target reads we proceeded to screen 171 for CNVs in our full cohort of targeted panel samples from patients referred for genetic testing to 172 identify the cause of their diabetes or hyperinsulinism(16). We were able to detect 11 clinically 173 relevant CNVs both within and outside of the targeted regions ( (14) 
Estimates of precision and recall rely on the quality of the truth set 210
On-target CNV calling from a targeted panel was tested on the ICR96 data set in which the truth set 211 was verified by MLPA. The truth sets for the off-target CNV calling from targeted panel and exome 212 sequence data were generated from CNV calls from genome sequencing data. Genome sequencing 213 has a much higher coverage than that generated from only off-target reads which allows CNVs to be 214 called more accurately enabling them to be used as a truth set. GenomeStrip(25) was used to call 215 the truth set as it was designed to call CNVs from genome data and was not one of the tools under 216 examination in this study. However, it is possible that there could be some false positive and negative calls in the truth set. This would lower the precision and recall of the tools under 218 examination but should not bias the results in favour of a particular tool. 219
Sensitivity depends on the size of the CNV 220
Smaller CNVs are harder for all software to detect. For all tools tested the larger the CNV the better 221 the precision and recall, however SavvyCNV performs better than the other tools tested. SavvyCNV 222 detects CNVs above 1Mb with 100% recall in off-target data from both targeted panel and exome 223 data. 224
CNV calling can be optimised for precision or recall by adjusting configuration 225
When calling CNVs, precision and recall are a trade-off; high recall will maximise the number of true 226
CNVs that are called, with the consequence that it also reduces precision resulting in a large number 227 of false positive CNV calls. Different precision levels are appropriate in different situations, 228 influenced both by the experimental methodology and the aims of the project. When calling CNVs 229 on-target on a small gene panel there will be fewer false positive calls generated due to the smaller 230 target area thus it may be preferable to adjust settings to enable a higher recall at the cost of a 231 lower precision. This could also be true in a clinical context where the most important aim is to not 232 miss a true causative variant. In contrast, when calling CNVs genome-wide in a gene-agnostic 233 approach such as genome sequencing, a higher precision is likely to be desirable to avoid generating 234 an unmanageably long list of CNVs. The user can choose their preferred settings for SavvyCNV for 235 different project requirements. 236
Off-target CNV calling is 'free' data and increases diagnostic yield 237
SavvyCNV utilises data already generated by targeted panel and exome tests. These tests are carried 238 out in order to detect single nucleotide variants and small insertions or deletions (<50 base pairs). In 239 some laboratories CNVs are also detected within the targeted regions using CNV calling software 240 while other laboratories use array-CGH or MLPA to detect CNVs. Using SavvyCNV allows CNVs to be detected not just within the targeted regions but allows genome-wide CNV calling. This will provide 242 a genetic diagnosis for more patients, increasing the diagnostic yield of these tests. We have 243 demonstrated the ability to find relevant genetic diagnoses using off-target CNV calling from our 244 small targeted panel. Existing data can be reanalysed with our method to reveal additional CNVs. As 245 an illustration of this, two of the CNVs in the ICR96 data set were found to actually be large CNVs 246 (15Mb and 56Mb), which may have clinical implications beyond the targeted gene. 247
Conclusions 248
SavvyCNV calls CNVs from off-target reads from exomes and small targeted gene panels with high 249 precision and recall, and performs better than existing tools including those designed for off-target 250 CNV calling. Calling CNVs from off-target reads is exploiting 'free' data to increase the diagnostic 251 (25) from the genome sequencing data. In order to remove 275 false positive calls CNVs were filtered based on their allele balance ratios -whether the allele 276 balance of the variants within the called CNV was consistent with it being a true call. We used the X 277 chromosome in males to calibrate the expected allele ratio for a deletion and used the allele ratio of 278 normal, two copy regions to evaluate if the allele ratio for duplications fell above that. In addition 37 279
CNVs were added to the targeted panel truth set as they were validated by other methods such as 280
Multiplex Ligation-dependent Probe Amplification (MLPA) or were aneuploidies reported by the 281 clinician at time of referral for genetic testing. 282
The ICR96 data set (19) was used to benchmark on-target CNV calling. This data set consists of 96 283 samples sequenced on a targeted panel where the truth set of CNVs is based on 68 positive and 284 1752 negative MLPA tests. 285
Calling clinically-relevant CNVs 286
The remaining 2479 targeted panel samples from unsolved patients with MODY, NDM and HH were 287 analysed with SavvyCNV to look for off-target CNVs which might explain their phenotype. For clinical 288 evidence of the CNVs, see Table 4 . 289
CNV tool comparisons 290
To ensure a fair comparison between the different tools, for each data set all tools were run with a 291 variety of configurations. The size of genomic regions that were analysed was varied for all five tools 292 (targeted panel: 150,000bp to 300,000bp; exomes: 6,000bp to 50,000bp; ICR96: 200bp to 600bp). 293
The hidden Markov model transition probability was varied for DeCON and SavvyCNV (10 -10 to 0.1). 294
All five tools provide quality metrics for the CNV calls. These metrics were used to filter the CNV calls 295 to reject false positive calls and retain true positive calls. All possible quality cut-off values were 296 tried. The best precision achieved for each possible recall was then selected for each tool from all 297 the generated results, and plotted in precision-recall graphs. EXCAVATOR2(14) did not run on the 298 ICR96 dataset -we contacted the authors of the tool but did not receive a response. 299
Statistics 300
We defined recall as the percentage of true positive CNVs that were found by the tool. We defined 301 precision as the percentage of the total CNVs called by the tool that were true. Several figures use 302 the f statistic to compare tools; this is the harmonic mean of precision and recall. 303 The study was conducted in accordance with the Declaration of Helsinki. 310
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